ev Transportation Services (“evTS”) is a designer, developer and manufacturer of all-electric lightweight commercial vehicles and fleet management solutions. The company is focused on the essential transportation services market. End-user applications for evTS vehicles include security, parking enforcement, local small package delivery, meter reading, sanitation, parks and recreation, university and corporate campuses, and warehouse operations services. A recent article discussing evTS reads, “The company’s flagship product is the FireFly ESV(R), a high-performance, low-maintenance electric vehicle with zero emissions. This utility vehicle was created specifically to meet the needs of essential services users. The FireFly ESV utilizes the safest Lithium Ion battery technology available (LiFePO4, Lithium Iron Phosphate) for superior acceleration, improved energy efficiency and enhanced reliability. As a result, it boasts a range of 100+ miles on a single charge, further than any other electric vehicle in its class.”
evTS designs, develops and manufactures all-electric, lightweight commercial utility vehicles and fleet management solutions. Based in Boston, the company is currently focused on the essential services transportation market, which represents a replacement market of approximately 100,000 vehicles or roughly $2.5 billion annually. End user applications for the company’s vehicles include, among others, parking enforcement, security patrol, utility meter reading, parks & recreation, sanitation, airports, seaports, universities, warehouses & fulfilment, and local small package delivery. More information can be found at http://evtaas.com.
NOTE TO INVESTORS: The latest news and updates relating to evTS are available in the company’s newsroom at https://ibn.fm/EVTS
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and health care platform, today announced that management will present at the Virtual Fall Investor Summit, hosted by Investor Summit Group and taking place November 16-18, 2020. According to the update, Trxade CEO Suren Ajjarapu is scheduled to participate in one-on-one meetings throughout the event and will host a virtual presentation at 2:30 p.m. Eastern Time (11:30 p.m. Pacific Time) on Tuesday, November 17, 2020. Interested parties may visit https://ibn.fm/gf2UL to register for the event and access the live webcast and archive of the presentation.
Headquartered in Tampa, Florida, Trxade Group is an integrated drug procurement, delivery and health care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health care services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms: (1) the Trxade B2B trading platform with around 11,800 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; and (3) the Bonum Health platform offering affordable telehealth services. For additional information, please visit www.Trxade.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
SGTM completes two-year audit in preparation for upcoming SEC Form-10 filing
Company targets fully reporting status, NASDAQ tier listing
Subsidiary to supply mulch products, services to Midwest, Western New York 7-Eleven stores
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has completed a two-year (2018 and 2019) audit in preparation for its upcoming SEC Form-10 filing (https://ibn.fm/uTDvF). The filing is part of SGTM’s strategic plan to become fully reporting and apply for uplisting.
“I’m truly blessed and proud of my team not only to complete our first two-year audit but to witness our catapult achievement,” said SGTM CEO and director Tony Raynor. “It’s thanks to my team and partners we have been able to achieve so much and progress with continue growth. Now with our audit complete, we are able to take our next major step on taking SGTM fully reporting and work our way to ultimately achieving NASDAQ tier listing.
“We are currently in discussion with multiple SEC legal counsel firms to see whom would fit best with our team and assist us on not only achieving every step along the way to be listed on the NASDAQ but to assure that we stay complaint with the SEC to provide transparency to our shareholders,” Raynor continued. “We plan on uploading our September 2020 quarter early November and updating our shareholders on our FORM-10 process as we progress.”
SGTM reported that the completed audit totaled $2,084,725 in revenue and $103,343 gross profit for FY 2019, respectively, and $508,591 in revenue and ($9,609) in gross profit for FY 2018. The company also recorded $18,637,665 in revenue and $5,081,772 gross profit for its June 2020 six-month uploaded quarter, which represents a 794% increase in revenue and 4,817% increase in gross profit compared to 2019’s operations.
In other good news for the company, its wholly owned subsidiary Mulch Manufacturing Inc. received an order to supply mulch products and services to 7-Eleven stores located throughout the Midwest and Western New York (https://ibn.fm/b52yJ). The contract, which is the most recent in an impressive list of contracts Mulch has nailed down in the last several weeks, starts in 2021.
“Thanks to our VP of sales Paul Stolly, we continue to secure major international chain accounts to start 2021 strong, commencing with 7-Eleven Inc.’s Midwest U.S. and western New York locations,” noted Raynor. “This allows us to build brand integrity and supply for future expansion as we progress.”
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. SGTM’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers.
The Sustainable Green Team plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. SGTM’s customers include governmental, residential and commercial clients.
To learn more about Sustainable Green Team Ltd., view the company’s investor presentation at https://ibn.fm/reoNg.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has announced an upcoming conference call. During the call, SRAX management will discuss the company’s Q3 financial report. The call is scheduled for Nov. 16, 2020, at 9 a.m. PT. SRAX founder and CEO Christopher Miglino and SRAX CFO Michael Malone will lead the call, which will provide an operational and financial summary of SRAX’s 2020 third-quarter numbers. Anyone interested in the presentation should register early to participate in the presentation; the live call can also be accessed by dialing 1-669-900-6833 and using the webinar ID# 942 4818 0377. In addition, a recording of the call will be available on the company website for 90 days.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, please visit www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Data shows that, when compared to persons without HIV, people with HIV have a shorter life expectancy and undergo accelerated aging by up to 10 years. These trends have been linked to prolonged inflammation and may cause the premature onset of diseases associated with age, such as neurocognitive decline, cancers and atherosclerosis.
The research findings were in the “Journal of Infectious Diseases,” and its findings highlight the need to create new treatments that target continual inflammation among people with HIV to improve outcomes.
When a person is infected with the HIV virus, the virus becomes part of his or her DNA forever. The affected cells don’t reproduce the virus, and to avert HIV/AIDS-linked complications, people usually use antiretroviral treatments. However, these treatments don’t avert chronic inflammation, which plagues most people living with HIV.
A physician scientist from the Boston Medical Center, Nia Lin, says that the main focus of the study was to find a link between chronic inflammation within HIV patients with suppressed virus loads and HIV latently infected cells.
To conduct the study, the researchers involved a group of 57 people living with HIV; these participants were treated using ART (antiretroviral therapy). Researchers compared virus measurements between the older and younger people with HIV as well as the inflammation detected in blood samples. The inflammation’s ability to set in motion HIV production originating from the dormant cells was also compared to the existing HIV genome.
The researchers’ findings point to the limited ability to manage the production of HIV RNA, even when using antiretroviral drugs, is connected to inflammation. The study’s corresponding author and infectious diseases physician Manish Sagar states that results suggest that new treatments that target the persistent inflammation in people with HIV is needed. While present-day ARVs prevent a new infection, they don’t avert RNA production in HIV cells.
Estimates indicate that approximately 1.2 million people in the United States are living with HIV. In addition, roughly 14% aren’t even aware that they’re infected. A different Centers for Disease Control and Prevention report states that among those who are undiagnosed or diagnosed with HIV two years ago, 65% had undetectable HIV viral loads, 58% were held in care and 76% had received a form of HIV care. To reduce the transmission risk to almost zero and prevent the progression of HIV, antiretroviral therapy is used.
One biomed company you should watch is Processa Pharmaceuticals Inc. (NASDAQ: PCSA). This Maryland-based company focuses on identifying potential drugs with proof of concept and then undertaking clinical trials to bring those remedies to market.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of pressure-based instruments, consumables and platform solutions to the worldwide life sciences and other industries, today announced the award of the first U.S. patent for its revolutionary Ultra Shear Technology(TM) (UST(TM)) platform. The patent, entitled “System for High Pressure, High Shear Processing of Fluids,” brings the company’s intellectual property (“IP”) estate to a total of 26 issued patents. “Nanoemulsions have long been shown to exhibit improved absorption, higher bioavailability and greater stability, while often requiring lower levels of emulsifiers than macro/micro emulsion products,” said Dr. Edmund Y. Ting, Sr., vice president of engineering of PBI and the inventor on the patent. “Because of these significant advantages, nanoemulsions are currently the focus of numerous research efforts worldwide. However, cost-effective scale-up of high quality nanoemulsion processing at a commercial level continues to be quite challenging. Importantly, we believe that PBI’s innovative and now patented UST platform can provide the key to commercial success for nanoemulsion products.”
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Pressure BioSciences’ primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Predictive Oncology CEO Carl Schwartz featured on NNW’s podcast to discuss the company’s prospects
Schwartz elaborated on company’s various divisions, affirming that POAI had begun to see revenue trends stabilize, cash burn rates decline
TumorGenesis received overwhelmingly positive feedback on its initial product launches, with plans to extend its technological prowess to address other oncological segments
Soluble Biotech, which announced its first major contract in August, is expected to reveal news of second order win in near future
Schwartz touched upon POAI’s Helomics business, stating his belief that division could soon transition towards monetizing its unique and one-of-a-kind asset portfolio
Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was recently featured in an exclusive audio interview with NetworkNewsWire (“NNW”), a financial news and content distribution company, to provide an update on the company’s recent milestones and near-term goals following the October release of his open letter to Predictive Oncology’s shareholders (https://ibn.fm/XLY14). During the wide-ranging conversation, Schwartz sought to update listeners on the company’s subsidiaries – Skyline Medical, TumorGenesis, Soluble Biotech and Helomics (https://ibn.fm/Vqkh5).
Schwartz commenced by outlining the status of the company’s Skyline Medical business, charged with overseeing the manufacture and sale of their proprietary STREAMWAY system – designed to provide medical facilities with a direct-to-drain fluid disposal system. The CEO revealed that although the company had sought to reduce emphasis on its legacy division, the company had sold 18 STREAMWAY units thus far in 2020 with the expectation of selling between 5-7 more over the course of the year.
Moreover, he explained that the business was throwing off an estimated $700 thousand in annual free cash-flows—a figure which has proven to be more than sufficient to cover the unit’s operating expenses.
Schwartz went on to elaborate on the TumorGenesis business, which specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians identify which cancer cells bind to specific biomarkers. He revealed that the company had received overwhelmingly positive feedback in regards to the division’s initial product launch and stated that the company would seek to extend its technological prowess towards addressing oncological segments such as lung cancer in the future.
The interview later transitioned to POAI’s most recent acquisition, Soluble Biotech, which seeks to provide optimized FDA-approved formulations for vaccines, antibodies and other protein therapeutics in a faster and lower cost basis to its customers. In August 2020, the company announced its first contract with a major pharmaceutical company for protein expression and solubility studies, and Schwartz stated that a second significant contract would be announced in the near future. Going forward, the CEO expressed his optimism on further contract wins as well as the award of certain grants, which had been applied for by the division.
Schwartz also touched upon Predictive Oncology’s outlook for the fourth quarter – placing particular emphasis on the prospects of the company’s Helomics business. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer case tumors to build AI-driven models of tumor drug response with the hope of improving outcomes for the patients of today and tomorrow. With the wealth of knowledge and experience gleaned over its operational lifespan, Schwartz affirmed his belief that Helomics was well on its way towards monetizing its exceptional and one-of-a-kind asset portfolio and validating the ambitions that POAI had harbored for the division upon its purchase a little over two years ago.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Wednesday, November 11th, 2020UncategorizedComments Off on $POAI CEO Joins NNW Podcast to Discuss Company’s Prospects; Provides Update on POAI Subsidiarie
iClick Interactive (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, has entered into an agreement to acquire the entire issued share capital of CMRS Group Holding Limited (“CMRS”). CMRS, a leading marketing automation solution provider based in Hong Kong, owns proprietary technology designed to aggregate data from multiple sources to help companies offer improved customer relationship management (“CRM”) services. Through the planned acquisition, iClick anticipates being able to enhance its already full product offerings, specifically for cross-border customers marketing into China. In addition, iClick expects that CMRS’s proven profitability, resources and potential to cross-sell iClick products will strengthen iClick’s Enterprise Solutions’ bottom line. The planned acquisition, comprised of cash and iClick American depositary shares, is subject to customary conditions. “We’re delighted to announce this deal between iClick and CMRS, which brings together two of the region’s leading innovative marketing solution providers,” said iClick co-founder and CEO Jian “T.J.” Tang in the press release. “By tapping into CMRS’s strengths in CRM, social media and cross-channel marketing automation, iClick will be able to expand the scope and effectiveness of our fast growing integrated enterprise and marketing solutions offerings. We are confident that this partnership will significantly enhance our ability to help brands adapt and succeed in today’s rapidly digitalizing market environment.”
iClick Interactive is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, the company’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in 10 locations worldwide including Asia and Europe. For more information about the company, please visit www.iClick.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Benzinga, an innovative financial media outlet that has developed a strong reputation for hosting unique and well-regarded events, has announced a new investor conference series: the Benzinga Global Small Cap Conference. The first event in the series is scheduled for Dec. 7, 2020, and will be completely online. This new event series is specifically designed to bridge the gap between publicly traded companies, investors and traders, and will provide an effective avenue for small-cap companies to network and communicate with a broad and diverse investor base. In addition, the Benzinga Global Small Cap Conference offers a series of educational modules that provides newcomers with an introduction to small-cap investing. A highlight of the conference will be the presentation of a specially curated group of small-cap investment opportunities. The daylong conference agenda features live, 15-minute company presentations held concurrently with live breakout sessions. Speakers at the conference will include Stephen Ehrlich, CEO of Voyager Digital Ltd. (OTCQB: VYGVF); Roney Varner, president and CEO of Genprex (NASDAQ: GNPX); John Temperato, CEO of 9 Meters Biopharma Inc. (NASDAQ: NMTR); and Bal Bhullar, CFO and director of ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO). “The Benzinga Team have always prided themselves in enabling our participating companies to form a series of deep and meaningful relationships with the wide variety of investors in attendance,” said Benzinga EVP Nicole LaPointe in the press release. “The Benzinga Global Small Cap Conference will mark our foray into a sub-sector of the global listed company universe, which has historically outperformed its larger-cap brethren yet still lacks the investor recognition and networking opportunities afforded to their larger peers. We believe that our conference will help address that historical imbalance by providing an outlet through which investors can interact and learn more about some of the most exciting and innovative companies operating across the world today.”
Benzinga is a leading financial media company dedicated to making information easier to consume. Benzinga’s news desk is constantly breaking stories and moving billions of dollars of market capitalization through its real-time news tool, Benzinga Pro. Benzinga’s original content is syndicated to 70 partner websites including Yahoo! Finance MSN, CNNMoney, Fox Business and MarketWatch. For more information about the company, please visit www.Benzinga.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its senior vice president of intellectual property and licensing, Thomas Gallagher, will participate at the annual NYC-based Life Sciences Summit. Gallagher will take part in a panel discussion titled, “Show Me the Money: Preparing Your Company for Funding,” at the event, slated to place virtually November 17-18, 2020. During the panel discussion, scheduled for 10-10:45 a.m. ET on Tuesday, November 17, experts will provide insight into the essential building blocks needed for emerging companies to reach their goals. Interested parties should visit https://ibn.fm/TgVGS to register for the event.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s web site atwww.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
XIAMEN, China , Nov. 11, 2020 — Blue Hat Interactive Entertainment Technology (“Blue Hat” or the “Company”) (NASDAQ: BHAT) , a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China , today announced it has received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
The notification has no immediate effect on the listing of the Company’s common shares on Nasdaq.
In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until May 5, 2021, to regain compliance with the minimum bid price requirement during which time the Company’s ordinary shares will continue to trade on the Nasdaq Capital Market. If at any time before May 5, 2021 the bid price of the Company’s ordinary shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement. In the event the Company does not regain compliance by May 5, 2021, the Company may be eligible for additional time to regain compliance or may face delisting.
The Company intends to monitor the closing bid price of its ordinary shares between now and May 5, 2021 , and intends to cure the deficiency within the prescribed compliance period.
About Blue Hat Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China , including interactive educational materials, mobile games, and toys with mobile game features. The Company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the Company’s investor relations website at . The Company routinely provides important information on its website.
Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the Company’s SEC filings. These risks and uncertainties could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements.
Contacts :
Blue Hat Interactive Entertainment Technology
Phone: +86 (592) 228-0010
Email: ir@bluehatgroup.net
In a study published in the “European Journal of Preventive Cardiology,” research findings show that children from mothers who had healthy lifestyles lived almost 10 years longer without cardiovascular diseases as compared to kids with mothers with unhealthy lifestyles.
Dr. James Muchira, the study’s author from Vanderbilt University, says that the study proposes that mothers are the main guardians of their offspring’s health.
Prior research shows that parents pass on health to their children through shared lifestyle or environment and genes. This pioneer study by Muchira is the first that looks into whether a parent’s heart health is linked to the age at which children develop cardiovascular disease. The study examined the influence of each parent individually.
The study was based on a child-mother-father trio model and involved a total of 5,967 people, with the number of fathers, mothers and offspring numbering 1,989 each. The children who were enrolled in the study in their early 30s were observed over a 46-year period (1971–2017) into their adult lives when strokes and heart attacks occur.
The researchers rated the cardiovascular health of fathers and mothers according to the following factors: blood glucose, blood cholesterol, blood pressure, healthy diet, physically active lifestyle, body mass index and smoking habits. Cardiovascular health was grouped into three categories: ideal (five to seven factors achieved), intermediate (three to four factors achieved) and poor (two or under). The researchers then evaluated any links between how long children lived without cardiovascular disease and parental cardiovascular health. They assessed the association between each pair, i.e., father-son, father-daughter, mother-son and mother-daughter.
While their results show that the father’s heart health had no significant effect on the period of time a child lived without cardiovascular disease, data did show that the risk of offspring suffering from early onset cardiovascular disease was twice as high if a mother had poor cardiovascular health.
Muchira explained that this strong maternal contribution was possibly a combination of environment and health status during pregnancy and into early life. He noted, however, that sons were more affected by a poor maternal health lifestyle than daughters. This, he noted, was mainly because sons had more detrimental lifestyles, which only made the situation worse. He added that people who inherited a high risk from their mothers could decrease that risk by eating well and exercising.
AzurRx BioPharma Inc. (NASDAQ: AZRX) is a biopharmaceutical firm whose specialty is using recombinant proteins to develop treatments for gastrointestinal conditions.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Wednesday, November 11th, 2020UncategorizedComments Off on $AZRX Mothers’ Lifestyles Provide Pointers to Likely Onset of Stroke or Heart Attacks in Offspring
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that its lifestyle brand A88CBD(TM) will introduce new powder packs in four exciting flavors available by the end of November. “We are thrilled to announce another exciting and innovative product for our A88CBD ingestible line,” said WTER president and CEO Ricky Wright. “Recently, we have added multiple category-leading items to our portfolio of products that differentiate us from competitors. Initial feedback has been overwhelmingly positive, resulting in strong online sales. Our latest addition, the A88CBD powder packs, tastes great and carries the same high-quality, lab-tested CBD that is fully dissolvable in any food and beverage. With commitments from over 500 retail locations, we expect this highly anticipated product to be a hit in the all-natural channel, especially with the support of our growing CBD partner network. These powder packs will be available in four exciting flavors and are perfect for the on-the-go consumer looking for a quick boost with fast onset times. Our loyal customers can drop these powder packs into their favorite A88 products to create an energizing and refreshing drink.”
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
PGA, MLB changes CBD policies; other leagues evaluating policy changes regarding marijuana, CBD use
Global market for CBD oil projected to grow from $967.2 million in 2020 to $5.3 billion by 2025
WTER offers an exclusive line of A88CBD(TM) products, ranging from tinctures, capsules and gummies to lotion, creams salves
Since CBD was removed from professional golf’s banned substance list in 2018, PGA and Champions Tour players are turning more frequently to the plant to treat aches and pains, and golfers aren’t the only athletes to choose the compound. Earlier this year, Major League Baseball removed marijuana from its banned-substance list during the offseason (https://cnw.fm/wNnWg). The benefits of CBD use by athletes are still being studied, but the Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) offers an exclusive line of A88CBD(TM) products (https://cnw.fm/nAIrd) that provide those benefits to sports enthusiasts — and anyone else looking for high-quality CBD-infused options.
“Billy Horschel went six months without a top-eight finish last year before he found a remedy for his ailing golf game from a surprising source: the hemp plant,” reported a recent “New York Times” article (https://cnw.fm/cH4CI). “Horschel, a five-time PGA Tour winner, began using cannabidiol, or CBD, products shortly after he missed the cut at the British Open in July. He had four top-eight finishes in the next four months and was playing some of the most consistent golf of his career before the season was suspended in March because of the coronavirus pandemic. . . . He is the latest in a growing group of tour members, including Bubba Watson, a two-time Masters champion, and Scott McCarron, the reigning Schwab Cup winner on the Champions Tour, who are paid endorsers for CBD products.”
In addition to golf and the MLB, an ESPN article reports that CBD use is allowed in the National Women’s Soccer League. The substance is currently prohibited in the NFL, NBA, MLB and NHL. However, “the NBA has also expressed interest in revising its bylaws against CBD use. In 2018, CBD was removed from the World Anti-Doping Agency’s banned substances list” (https://cnw.fm/ZkgFm).
The same article noted that CBD, short for cannabidiol, “has often been touted as a cure-all of sorts. Manufacturers and users claim, mostly anecdotally, that it has given them relief from muscle soreness and swelling and helped curb stress and anxiety. . . . Hemp-based CBD is legal — in various forms from ingestible oils to topicals — in all but three states in the U.S. and is legal at the federal level. States have their own rules restricting or allowing CBD products to be sold, and in many states, CBD can be sold over the counter in drug stores. It remains unregulated by the Federal Drug Administration, however.”
The ESPN article reported that the global market for CBD oil should grow from $967.2 million in 2020 to $5.3 billion by 2025 — all without CBD brands being allowed to directly advertise their products on social media.
WTER chairman Aaron Keay, a former Canadian national soccer team member, is an advocate for CBD use in sports, as well as other aspects of everyday use. “If you look at the kind of the athlete adoption of it, it kind of coincides with how the world is taking it on and looking at it. But you have a few movers and shakers that are willing to take the risk and say: ‘Look, CBD is going to become mainstream way ahead of cannabis and THC,’” Keay told ESPN. The Alkaline Water Company Inc. is a proud supporter of sports; the company’s brand ambassador Chez Reavie, who wears WTER’s flagship Alkaline88 logo on his shirt and sports an Alkaline88 golf bag at all PGA events, won the 2019 Travelers Championship Tournament.
The Alkaline Water Company offers an exclusive line of A88CBD(TM) products, ranging from tinctures, capsules and gummies to lotion, creams salves. The A88CBD products are formulated using high-quality, U.S.-grown hemp and made with 100% natural ingredients, cruelty-free, and gluten-free ingredients.
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. In 2019, Alkaline88 launched A88 Infused(TM) to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020 the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has released its financial information, reporting another profitable quarter. A highlight of the report indicates that the company’s revenues have totaled $24.5 million for the first nine months of 2020. Numbers for the report include both the three months ending Sept. 30, 2020 and the nine months ending Sept. 30, 2020. SGTM’s financial totals for the quarter include $5,907,155 in revenue, $422,133 in gross profit and $36,140,923 in total assets, with a strong position of $5,936,798 in cash and liquid investments. For the nine-months period, the company announced $24,544,820 in revenue and $5,503,905 in gross profit. Other highlights of the announcement included notice that SGMT completed a company name and trading symbol change. The company also received permit approval to accept debris and manufacture mulch at its largest state-of-the-art facility as well as IPEMA certification to recycle tree and storm waste into public playground surfacing material, which allows SGTM to enter that a market valued at $4 billion market. “I am proud of our team and the progress we have made this year in achieving these key milestones,” said SGMT CEO and director Tony Raynor in the press release. “We plan to proceed in a similar manner during the remaining quarter and end 2020 on a strong note. In keeping with that aim, we have already completed our two-year audit to commence our Form 10 process, which will enable us to begin 2021 as a fully reporting company and uplist accordingly.”
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential, and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit http://ibn.fm/NYk36
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, is scheduled to host a conference call to discuss its third quarter 2020 results at 9:00 a.m. PT on November 16, 2020.
SRAX’s Founder and CEO, Christopher Miglino, and CFO, Michael Malone, will provide an operational and financial summary of the third quarter of 2020.
The webcast will be available on srax.com for at least 90 days. To dial-in to the conference call, please call US: +1 669 900 6833. Webinar ID: 942 4818 0377.
About SRAX
SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire , companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com .
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in our business, and our need for future capital. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in SRAX’s periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.
Tuesday, November 10th, 2020UncategorizedComments Off on $SRAX to Host Third Quarter 2020 Financial Results Conference Call on Monday, November 16, 2020
Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D metal printing industry, today announced that management will present at the Virtual Fall Investor Summit taking place from November 16 – 18, 2020. According to the update, Sigma Labs CEO Mark K. Ruport is scheduled to host a virtual presentation at 9:00 a.m. ET on Wednesday, November 18, 2020, and will also participate in one-on-one meetings throughout the day. Sigma’s presentation will highlight its new PrintRite3D Lite In-Process Quality Assurance system, IN4.OS Strategic Alliance for Factories of the Future and recent contract awards. Interested parties may visit https://ibn.fm/G6mFY to register for and access the event.
Sigma Labs is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.SigmaLabsInc.com.
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
A new analysis conducted by the Imperial College London has assessed the weight and height of adolescents and school-aged children around the globe. The study, which was published in “The Lancet” journal, used the data of 65 million children, all aged between 5 and 19, from 193 nations around the world.
The analysis discovered a 20 cm difference between children aged 19 in the shortest and tallest nations. This represents a six-year growth gap and an eight-year one for boys and girls respectively. The team of researchers who conducted the study warned that a lack of quality food with regard to childhood nutrition may lead to a rise in childhood obesity and stunted growth. This affects children’s well-being and health for their entire lives.
Using data from 1985–2019, the researchers revealed that the countries with the shortest 19-year olds were mostly in East Africa, Latin America, and Southeast and Southern Asia, including Bangladesh, Guatemala, Papua New Guinea and Timor-Leste. The countries that had the tallest 19-year olds were in Central and Northwest Europe, including Iceland, Denmark, Montenegro and the Netherlands.
The study noted that in the last 35 years, world height ranking for the UK had worsened, with 19-year old girls falling from 42nd place at 162.7 cm tall in 1985 to 49th place at 163.9 cm in 2019. The boys also dropped to 39th place at 178.2 cm from 28th place at 176.3cm.
In emerging economies such as South Korea, China and parts of Southeast Asia during the same 35-year period, large improvements in children’s average height were recorded. On the other hand, the height of children — especially boys — in many sub-Saharan African countries has reduced or stagnated in this three-and-a-half-decade period.
The research also evaluated the BMI of the children, which is the measure of weight and height ratio. This measurement indicates if a person has a healthy weight for their height. The researchers discovered that 19-year olds with the lowest BMI’s were in Southern Asian nations such as Bangladesh and India while those with the highest BMI’s were found in New Zealand, the United States, the Middle East and the Pacific Islands. In the study, the difference between the heaviest and lightest BMI’s was about 9 BMI units, which in weight talk is approximately 25kg.
The study’s analysis revealed that after the age of five, children in some nations gain too much weight while not experiencing a comparative increase in height. This is despite the potential for healthy growth as defined by the World Health Organization. The researchers state that this is mostly due to a lack of sufficient and healthy nutrition, as both weight and height gains of a child are closely linked to the quality of their diet.
Predictive Oncology (NASDAQ: POAI) is an interesting company that you should watch. The firm leverages its resources and industry collaborations to identify the best ways through which personalized treatments can be brought to cancer patients.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
The United Kingdom was the first major economy to pass a net-zero emissions law, and the country plans on bringing all greenhouse gas emissions to net-zero by 2050. Several automakers have announced plans to reduce and ultimately stop the production of fossil-fuel-powered vehicles in favor of electric vehicles; recently, British automaker Bentley announced what appears to be the most ambitious plan of all. The luxury carmaker has pledged to stop making all fossil-fueled cars by 2030 in favor of all-electric electric vehicles (“EVs”) with zero carbon-exhaust emissions.
Initially, Bentley will stop the production of internal-combustion engine-powered vehicles within the next six years. The company will start developing hybrid cars, producing its first battery electric vehicles in 2025. By 2030, the company plans on its entire lineup consisting of electric vehicles only. “Within a decade, Bentley will transform from a 100-years-old luxury car company to a new, sustainable, wholly ethical role model for luxury,” said Bentley’s chief executive Adrian Hallmark.
The plan was announced Nov. 5, 2020, as part of the British luxury carmaker’s Beyond100 strategy, which will see the firm become an “end-to-end carbon neutral car brand.” According to “Car and Driver,” Bentley is set to hit the road running. Starting next year, Bentley will offer two hybrid plug-in models: the Bentayga Hybrid and the all-new Flying Spur Hybrid. “Car and Driver” reports that every Bentley model will be available with a hybrid powertrain by 2023.
The luxury carmaker will start production of its first fully-electric vehicle in 2025. “The future of Bentley will be fully electric,” said the firm’s chief engineer Matthias Rabe during an event announcing the news. Bentley is already taking steps towards reducing its impact on the environment. Last year, its production facility in Crewe was certified carbon neutral, becoming the first luxury automotive factory in the UK to earn the distinction.
The certification was granted due to Bentley’s two decades of implementing environmentally friendly solutions such as installing water recycling systems in paint shops and transitioning to renewable-only sources of electricity. The automaker states that all of its suppliers will have passed a sustainability audit as well by the end of the year.
“As a luxury car brand, our customers are more likely to have a home where they can charge a vehicle, an office where they can charge a vehicle, and other cars so they don’t have to rely on electric vehicles if they don’t quite meet their routine needs,” said Hallmark. “We are pushing to modernize and again reposition Bentley for a new generation.”
Net Element (NASDAQ: NETE) is an entity that you should watch in the electric vehicle sector. This financial solutions company announced in early August that it was merging with Mullen Technologies Inc., an EV maker based in California.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the addition of George K. Gittes, MD to its Scientific Advisory Board (“SAB”). According to the update, Dr. Gittes is the inventor of GNPX’s licensed diabetes gene therapy technology that is currently in development and serves as the chief of pediatric surgery and surgeon-in-chief emeritus at the UPMC Children’s Hospital of Pittsburgh. “We are delighted to have Dr. Gittes join our Scientific Advisory Board as Genprex continues to advance its diabetes program,” said Rodney Varner, Genprex’s president and chief executive officer. “It is imperative that we rely on the guidance and direction of esteemed individuals with a wealth of expertise in research and gene therapy, and I expect that Genprex will benefit greatly from Dr. Gittes’ experience. He will play an instrumental role in our efforts to bring new hope to patients who suffer from the devastating complications of this chronic illness.”
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s “Tagrisso(R)”) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information about the company, visit www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
With the ever-growing data that needs to be managed, the increasing demand to do more with limited resources and the current global pandemic, the natural resources sector has a lot to deal with.
Siloed devices and systems that don’t communicate with each other only add more to the demand. Frontline workers require crucial technology to manage their everyday tasks effectively. These tools have to be flexible enough to help them connect with a wider ecosystem of technologies,without any hitches.
To help with this, Motorola Solutions will launch its next-generation TETRA device, a terrestrial trunked radio. The device, MXP600, will meet the transportation sector’s needs. The highly rugged yet lightweight radio can collaborate with other solutions and elevates voice communication for workers to new levels.
The MPX600 not only boasts of mission-critical coverage but also an adaptive mission-critical audio. The device also supports four global navigation satellite systems including the U.S.’s GPS, Russia’s GLONASS, China’s Beidou and Europe’s Galileo system.
According to the Australian Mining Risk Forecast 2020/2021 by KPMG, the coronavirus pandemic has caused serious changes to the mining sector’s risk mitigation measures, including its decision making as well as immediate planning.
Martin Chappell, the general manager for minerals and energy for Motorola Solutions in both New Zealand and Australia, says that the mining sector will continue investing in tools and technology to increase productivity without putting the safety of its frontline personnel on the line. He mentioned that the safety of both the workers and the community remained the number-one priority for the sectors of the economy that provide essential services.
Furthermore, he explained that in remote and rugged mining environments, mission-critical radio provides the most secure, reliable and robust way for communication between frontline teams. He noted that initial tests of the MPX600 conducted in the mining sector had discovered that technology users especially valued the durable and lightweight radio design as well as its highly advanced audio features.
He then added that mining organizations would continue to invest in advanced mobile radio technologies to adopt new solutions that allow greater flexibility and collaboration with its Bluetooth feature and high definition voice hardware. This would also help to enhance safety during their firm’s operations. The MPX600 is equipped with end-to-end encryption, which ensures that data remains unexposed to insider threats.
It’s all about upgrading the main features of mission-critical communication while simplifying it, Chappell said.
Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) is a company you need to watch in the mining industry. UUUU has the enviable position of being the largest U.S. producer of two minerals (uranium and vanadium), which have both been designated by the government as critical minerals.
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Creatd (NASDAQ: CRTD), the parent company of Vocal, a proprietary technology platform for creators of all types, will hold a Nov. 17 webcast. During the webcast, company officials will discuss Creatd’s third-quarter 2020 financial numbers as well as provide key updates about business updates, including an overview of CRTD’s freemium creator and paid subscription metrics. In addition, the company will host a Q&A following the discussion of the financials. Questions can be submitted via the webcast portal or emailed (ir@creatd.com) prior to the webcast. Creatd anticipates releasing the company’s financial results after the market closes on Monday, Nov. 16, 2020. The Nov. 17 (Tuesday) webcast will begin at 11 a.m. ET. Anyone interested in participating on the call should register in advance. Those interested can also access a recording of the webcast on the company’s website following the session.
Creatd empowers creators, brands, and entrepreneurs through technology and partnership. Its flagship technology platform is Vocal; Vocal provides creators of all shapes and sizes, from bloggers to podcasters and more, with best-in-class storytelling tools, safe and curated communities, and the opportunity to monetize their content. With 34 owned and operated communities, Vocal enables creators to connect to their ideal audiences and to partner with the brands that want to reach those audiences. For more information about the company, please visit www.Creatd.com.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
In an opinion piece that was recently accepted for publication in the “Journal of Medical Ethics,” a leading ethicist argues that governments across the world should consider incentivizing individuals to get a coronavirus jab when the vaccine comes on the market. This will help reach the needed level of herd immunity. This may make up at least 80% of the population and will help eliminate the infection.
The incentive may be payment in kind or financial. Professor Julian Savulescu, the author of the piece, points out that with the rising worldwide death toll and the extensive economic and health consequences of the COVID-19 pandemic, many are calling for the coronavirus vaccination to be mandatory.
Generally, he says, vaccination is voluntary. However, if people don’t voluntarily get vaccinated, they may resort to vaccination plan B. This approach may include coercion for the public good and implementing mandatory vaccination policies. If a mandatory approach was to be used, he argues that ethical issues are bound to come up.
So if people don’t take to voluntary vaccination, governments should look into incentivization while increasing vaccination uptake. To make any vaccination program effective, a certain uptake level is needed. This will help rid us of the coronavirus pandemic.
Savulescu writes that for the vaccine to be most effective, about 82% of the population would need to be vaccinated, and despite the more obvious issues of manufacturing and administering a coronavirus vaccine to the global population, vaccine hesitancy seems to be on the rise. This is mainly because of safety concerns. Even with the lack of a vaccine in the market, many are already refusing or showing reluctance about getting vaccinated.
Vaccination is likely to be an even bigger issue when a new vaccine does reach the market. Therefore, any compulsory vaccination program would be required to make a value judgement about what level of certainty and safety are certain and safe enough. Savulescu explained that it was difficult to say if a mandatory coronavirus vaccination policy was ethically justified until scientists could evaluate the vaccine’s nature and the likely benefits and costs of alternatives.
He adds that while anti-vaxxers may never be convinced to shift their stance on all things vaccination, vaccine incentivization may convince other individuals who may have not yet gotten the jab to do so. Savulescu continues, explaining that incentivization isn’t encouraging individuals to take unreasonable risks. However, it makes economic sense to pay people to incentivize them to vaccinate.
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a player you should watch in the biomed space. The company focuses on developing organ-targeted therapies, particularly treatments for primary as well as metastatic cancers that afflict the central nervous system and the brain.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced its entry into a binding letter of intent (“LOI”) with Asymchem, a leading global contract development and manufacturing service (“CDMO”) provider, for the development and production of MS1819 for the treatment of exocrine pancreatic insufficiency. Under the agreement, Asymchem will implement fermentation, verify protein expression and ultimately fine-tune the technology suitable for production of MS1819. Asymchem will be responsible for sourcing all materials required for the program under Current Good Manufacturing Practice (“cGMP”) regulatory conditions. “With a fairly competitive landscape for CDMOs, we worked diligently to identify the right partner for our pivotal Phase 3 clinical trial,” said James Sapirstein, president and chief operating officer of AzurRx BioPharma. “Our entire team is very proud of how far we’ve come, and we are excited to move into the next chapter of our clinical development plans for MS1819 with reduced manufacturing costs in the commercial product of our drug. Asymchem has a successful track record working with top pharmaceutical companies in the industry, and I am confident our partnership will steer us on the right path of manufacturing optimization and ultimate commercialization of MS1819.”
AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Experts expect the recreational marijuana market in Michigan to rival the numbers currently seen in some of country’s top cannabis markets within the next few years
Gage Cannabis Co. is innovating and curating the highest-quality cannabis experiences possible for cannabis consumers in the state of Michigan
New Lansing location offers a wide range of products, all available for purchase through curbside delivery or walk-up pick up
Gage Cannabis is strengthening its position as Michigan’s leading high-quality craft cannabis brand and operator by offering recreational marijuana at its Lansing, Michigan location (https://nnw.fm/l6Jmy). The company is committed to building the fastest-growing cannabis brand in the state, which is currently home to one of the fastest-growing legal cannabis markets in the country.
“We are thrilled to start offering recreational sales to more customers within the Lansing area,” said Gage Cannabis Co. president Fabian Monaco. “The demand for adult-use products has exploded in the past year, and we are ready and eager to meet those needs. We have received an overwhelmingly positive response from medical patients about our products and retail experience, and we look forward to providing the same level of service and product selection to our new community of recreational customers.”
Gage’s Lansing location offers a wide range of products, all available for purchase through curbside delivery or walk-up pick up. The store’s product offerings include flower, pre-rolls, edibles, concentrates, topicals, tinctures, CBD products, accessories and apparel. The company also features products by Redemption Cannabis, which was founded by Ryan Basore, one of Gage’s first social-equity program recipients.
Through this program, Gage offers grants of up to $50,000 to help those who were harmed by the war on drugs. In 2019, Basore, who spent two and a half years in prison after his cannabis business was raided by authorities, received the grant from Gage Cannabis and used the funds to join with other drug-war victims and create the Redemption brand (https://nnw.fm/4QLnL).
In addition to its Lansing location, Gage has four additional locations up and running — Adrian (which also offers recreational marijuana), Detroit, Ferndale and Traverse City — with eight more locations coming soon. The company has plans to have more than 20 operating locations by the end of 2021.
Many experts expect the recreational marijuana market in Michigan to rival the numbers currently seen in some of the country’s top cannabis markets within the next few years (https://nnw.fm/LnGAt). An estimated 3% of Michigan’s residents hold medical marijuana cards, a much higher percentage than most other medical markets. A leading research organization predicts that the state’s recreational market could triple in size between 2020 and 2023.
Gage Cannabis Co. is innovating and curating the highest-quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the firm’s founding partners have successfully built and grown operations with federal and state licenses, including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 Class C cultivation licenses, three processing licenses and 13 provisioning centers (dispensaries). The company is currently planning a Canadian listing for early 2021 (https://nnw.fm/4O8Sw) and has launched a Regulation A, Tier 2, equity financing.
To learn more about the company’s Regulation A financing, visit www.GageInvestors.com.
For more information on Gage Cannabis Co., visit the company’s website at www.GageUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://nnw.fm/GAGE
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the successful closing of its transaction with KBL Merger Corp IV. Prior to the merger’s closing, KBL Merger Corp. changed its name to 180 Life Sciences Corp., and 180 Life Sciences Corp. changed its name to 180 Life Corp., which now operates as a wholly owned subsidiary of the company. As a result of the merger, the units and rights of KBL Merger Corp. ceased trading, and the shares of its common stock and warrants are now trading on the Nasdaq Capital Market under the ticker symbols “ATNF” and “ATNFW,” respectively. “We are excited to have completed the transaction resulting in 180 Life Sciences now being a public company. Not only does the company boast a tremendous pipeline of innovative therapies that use anti-TNF to treat inflammatory diseases, it also boasts an unparalleled team of pioneering and world-renowned scientists leading the charge – namely, Prof. Sir Marc Feldmann and Prof. Lawrence Steinman,” said Dr. James Woody, who leads 180 Life Sciences. “I look forward to working with them to discover new therapies to address inflammatory diseases, as well as building value for our shareholders.”
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://nnw.fm/ATNF
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
TAMPA, FL, Nov. 10, 2020 — Trxade Group, Inc. ( MEDS ) an integrated drug procurement, delivery and healthcare platform, today announced that management will present at the Virtual Fall Investor Summit, hosted by Investor Summit Group and taking place November 16-18, 2020.
Suren Ajjarapu, Chief Executive Officer of TRxADE Group, is scheduled to participate in one-on-one meetings throughout the event and will host a virtual presentation as follows:
A live audio webcast and archive of the presentation will be available using the webcast link above until November 16, 2021. For more information on the Investor Summit Group Virtual Fall Summit or to schedule a one-on-one, please contact the Company’s investor relations contact or your Investor Summit Group representative.
About Trxade Group, Inc.
Headquartered in Tampa, Florida, Trxade Group, Inc. (Nasdaq: MEDS) is an integrated drug procurement, delivery and healthcare platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making healthcare services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; (1) the Trxade B2B trading platform with around 11,800 registered pharmacies, (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division and (3) the Bonum Health platform offering affordable telehealth services. For additional information, please visit us at www.trxade.com and www.bonumhealth.com .
Investor Relations: Lucas Zimmerman
Senior Vice President
MZ Group – MZ North America
(949) 259-4987 MEDS@mzgroup.us www.mzgroup.us
Tuesday, November 10th, 2020UncategorizedComments Off on $MEDS to Present at the Virtual Fall Investor Summit
For the sixth consecutive month, Illinois has crushed yet another cannabis sales record, having reached a $500-million-worth benchmark of legal marijuana products that have been bought since the program was launched at the start of this year. Illinois has shown that its marijuana market is not only pandemic proof but also recession proof.
Last month, adults bought 1,557,880 cannabis products worth $75,278,200 cumulatively. That’s almost $8 million more than sales in September and about twice the sales recorded in January. These figures do not include purchases made through the state’s medical marijuana program. Based on this, to say the strides made in the market weren’t in the least impressive would be a blatant lie.
It is estimated that about $21 million of these recorded sales came from out-of-state tourists while roughly $55 million in purchases came from in-state residents. In addition, state officials announced in October that the state had surpassed $100 million in revenue due to the high sales. The revenue is being used to fund restorative justice programs and local governments.
Illinois state officials stated that the tax revenue from the market will be reinvested in communities that have been most affected by the drug war. Almost 25% of the tax revenue collected has been designated for restorative justice grants, and other funds will be used to support mental health and substance misuse treatment programs. In May, the state had announced that it would be making nearly $31 million in social equity grants available to communities that had been identified as economically distressed.
Additionally, before the state implemented its cannabis system, Illinois Gov. J.B. Pritzker pardoned more than 11,000 individuals with prior marijuana convictions. The governor also revealed in October that he would be granting more acts of cannabis clemency in the coming months. Amid the coronavirus pandemic, the recent sales numbers also strengthen the argument made by pro-reform lawmakers in various states.
However, not all parties are excited about this increase in sales. An alliance of state medical societies released a joint statement last week that criticized the efforts to legalize cannabis. These statements noted that the various societies appreciated the economic challenges states face as a result of the coronavirus pandemic but urged against legalization of cannabis as a way to address these challenges.
The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) is one cannabis sector player you should watch. The company started out providing premium alkaline water, and it has now set its sights on adding topical and ingestible hemp-infused products to its portfolio.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
Monday, November 9th, 2020UncategorizedComments Off on $WTER 420 with CNW – State Reveals Stores Have Sold Marijuana Products Valued at Half a Billion Dollars
iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced that it will report its unaudited third quarter 2020 financial results before the U.S. market opens on Tuesday, November 24, 2020. In addition, Jian “T.J.” Tang, ICLK CEO and co-founder, and Terence Li, ICLK CFO, will host a conference call to discuss the company’s business and financial performance at 8:00 a.m. U.S. Eastern Time (9:00 p.m. Hong Kong Time) on November 24, 2020. A live and archived webcast of the call, including earnings release and presentation slides, will be available on the company’s investor relations website. Interested parties may join the call by dialing +1-888-346-8982 (United States), +1-412-902-4272 (International), +852-800-905945 (Hong Kong) or +86-4001-201203 (Mainland China) and asking to join the iClick Interactive Asia Group Limited conference call.
iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe. For more information about the company, please visit ir.i-Click.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
The study was conducted in accordance with the NACLAR guidelines. The research team’s discovery demonstrates that immunoglobulin E, the main antibody in charge of triggering allergic reactions, can enter the fetus by crossing the placenta. Once inside the fetus, the antibody hitches itself onto fetal mast cells as observed in mice. Fetal mast cells are immune cell types that release the chemicals which trigger an allergic reaction, from asthma to runny noses.
The researchers noted that after birth, newborn mice develop allergic reactions to types of allergen that are similar to their mothers. These findings show that the maternal immunoglobulin E (IgE) can cross a human’s placenta in a similar way.
The senior co-author of the study, Dr. Florent Ginhoux, stated that despite the lack of knowledge surrounding mast cells present in a developing fetus, the study discovered that fetal mast cells matured phenotypically in the course of pregnancy and could be sensitized by maternal IgE that crossed the placenta.
Ashley St. John, an associate professor at Duke-NUS and senior co-author of the study, explained that allergies begin very early in life, with infants experiencing allergic responses that are closely connected to their mothers’ allergic response. Scientists could not explain if genetics were behind this, but the study’s findings seem to have captured interest by showing that allergic responses can be passed to the developing fetus from the mother and showing how allergies can endure after birth.
The study’s findings could be used to develop intervention strategies that limit the transfer of allergies, thus helping reduce neonatal allergy occurrences. Today, 10% to 30% of the global population is affected by allergies, and projections show that the number will continue rising. Developing a solution that stops allergies from being passed from a mother to her child may help bring down those numbers over time, according to the researchers.
A senior consultant with the KKH Department of Reproductive Medicine, Professor Jerry Chan says that from a clinical point of view, learning more about IgE placental transfer would be important in helping develop strategies to decrease the chance of transfer of eczema as well as other allergies from mothers to their infants.
The study’s authors now aim to understand how immunoglobulin E hitching onto mast cells in a fetus’s skin adjusts the newborn’s functions and how it may affect skin physiology after the fetus is born.
An interesting entity in the biotech space that you should watch is DarioHealth Corp. (NASDAQ: DRIO). The company focuses on creating digital therapeutics solutions aimed at helping sufferers of chronic conditions to make behavioral adjustments that improve the quality of their lives.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
